Австралия - английски - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - glimepiride, quantity: 1 mg - tablet, uncoated - excipient ingredients: iron oxide red; sodium starch glycollate type a; sodium lauryl sulfate; magnesium stearate; microcrystalline cellulose; lactose monohydrate; povidone - indicated as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with non-insulin-dependent (type 2) diabetes mellitus.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; silicified microcrystalline cellulose - flecain is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecain should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecain tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; croscarmellose sodium; magnesium stearate; maize starch - flecain is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecain should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecain tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: maize starch; magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; silicified microcrystalline cellulose; maize starch - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - oral contraception

Австралия - английски - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - oral contraception

САЩ - английски - NLM (National Library of Medicine)

micro labs limited - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k), chlordiazepoxide (unii: 6rz6xez3cr) (chlordiazepoxide - unii:6rz6xez3cr) - chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. the therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. chlordiazepoxide and amitriptyline hydrochloride tablet is contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants. it should not be given concomitantly with a monoamine oxidase inhibitor. hyperpyretic crises, severe convulsions and deaths have occurred in patients receiving a tricyclic antidepressant and a monoamine oxidase inhibitor simultaneously. when it is desired to replace a monoamine oxidase inhibito

Австралия - английски - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Австралия - английски - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -